4397-55-1

Basic information

• Product Name: methyl 2-(chlorocarbonyl)benzoate
• Synonyms: 2-METHOXYCARBONYLBENZOYL CHLORIDE;methyl 2-(chlorocarbonyl)benzoate;Methyl phthaloyl chloride 97%;o-Carbomethoxybenzoyl chloride;o-Methoxycarbonylbenzoyl chloride;Phthalic acid monochloride monomethyl ester;Methyl 2-chloroformylbenzoate
• CAS NO: 4397-55-1
• Molecular Formula: C₉H₇ClO₃
• Molecular Weight: 198.60308
• Mol File: 4397-55-1.mol

Chemical Properties

• Boiling Point: 297.3°C at 760 mmHg
• Flash Point: 130.5°C
• Appearance: /
• Density: 1.291g/cm³
• Vapor Pressure: 0.00136mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: 2-8°C
• CAS DataBase Reference: methyl 2-(chlorocarbonyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(chlorocarbonyl)benzoate(4397-55-1)
• EPA Substance Registry System: methyl 2-(chlorocarbonyl)benzoate(4397-55-1)

Safety Data

• Hazard Codes: C
• Statements: 22-34-43
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 4397-55-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
Methyl 2-(chlorocarbonyl)benzoate is used as an intermediate in the synthesis of various organic compounds, contributing to the development of new materials and products.
Used in Pharmaceutical Industry:
Methyl 2-(chlorocarbonyl)benzoate is used as a building block in the production of pharmaceuticals, playing a crucial role in the synthesis of drugs and other therapeutic agents.
Safety Precautions:
When handling methyl 2-(chlorocarbonyl)benzoate, it is essential to take safety precautions due to potential hazards associated with its use, ensuring a safe working environment and minimizing risks to health and the environment.

InChI:InChI=1/C9H7ClO3/c1-13-9(12)7-5-3-2-4-6(7)8(10)11/h2-5H,1H3

Upstream product

• 4376-18-5 Monomethyl phthalate 
• 85-44-9 phthalic anhydride 
• 7719-09-7 thionyl chloride 

Downstream Products

• 109510-44-3 2-(2-oxo-hexahydro-azepine-1-carbonyl)-benzoic acid methyl ester 
• 4388-29-8 [2,2'-biisoindoline]-1,1',3,3'-tetraone 
• 34006-78-5 methyl propyl benzene-1,2-dicarboxylate 
• 859033-58-2 2-(5,7-dihydroxy-3-methoxy-4-oxo-4H-chromen-2-yl)-benzoic acid 
• 34006-77-4 ethyl methyl phthalate 
• 73513-54-9 phthalic acid isobutyl ester-methyl ester 
• 858011-46-8 N-(β-methoxy-phenethyl)-phthalamic acid 
• 858011-45-7 N-(β-methoxy-phenethyl)-phthalamic acid methyl ester 
• 102182-10-5 N-[5-(4-nitro-phenoxy)-pentyl]-phthalamic acid methyl ester 
• 73513-53-8 phthalic acid 1-tert-butyl ester 2-methyl ester 
• 26593-43-1 2-methoxycarbonyl-N,N-dimethylbenzamide 
• 26593-44-2 o-Carbomethoxy-N,N-diethylbenzamide 
• 2346-63-6 2-(2,4-dimethylbenzoyl)benzoic acid 
• 53241-98-8 o-carbomethoxybenzoic acid anilide 

Relevant articles and documents

Palladium-catalyzed C–P bond activation of aroyl phosphine oxides without the adjacent “anchoring atom”

A novel palladium-catalyzed decarbonylation of aroyl phosphine oxides to prepare phosphine oxides from carboxylic acids is developed. Without the adjacent “anchoring atom”, the challenging C–P bond activation is achieved in high selectivity. The disclosure of this reaction provides a new example of C–P bond activation and helps to extend the understanding of the property of C–P bond.

Substitution Effect on 2-(Oxazolinyl)-phenols and 1,2,5-Chalcogenadiazole -Annulated Derivatives: Emission-Color-Tunable, Minimalistic Excited-State Intramolecular Proton Transfer (ESIPT)-Based Luminophores

Minimalistic 2-(oxazolinyl)-phenols substituted with different electron-donating and -withdrawing groups as well as 1,2,5-chalcogenadiazole-annulated derivatives thereof were synthesized and investigated in regard to their emission behavior in solution as well as in the solid state. Depending on the nature of the incorporated substituent and its position, emission efficiencies were increased or diminished, resulting in AIE or ACQ characteristics. Single-crystal analysis revealed J- and H-type packing motifs and a so-far undescribed isolation of ESIPT-based fluorophores in the keto form.

Aziridine-2-carboxylic acid derivatives and its open-ring isomers as a novel PDIA1 inhibitors

[Figure not available: see fulltext.] Acyl derivatives of aziridine-2-carboxylic acid have been synthesized and tested as PDIA1 inhibitors. Calculations of charge value and distribution in aziridine ring system and some alkylating agents were performed. For the first time was found that acyl derivatives of aziridine-2-carboxylic acid are weak to moderately active PDIA1 inhibitors.

Amide prodrug derivatives as protein kinase inhibitors

The invention relates to amide prodrug compounds of novel kinase inhibitors. The prodrugs are characterized in that amino of original drugs is subjected to amidation modification, so that bioavailability of the original drugs in vivo is significantly improved. The invention further relates to pharmaceutical composition containing the prodrugs and a method for treating cancer or other cell proliferative abnormal diseases by the prodrugs and the pharmaceutical composition.

Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold

Targeting CCR2 and CCR5 receptors is considered as promising concept for the development of novel antiinflammatory drugs. Herein, we present the development of the first probe-dependent positive allosteric modulator (PAM) of CCR5 receptors with a 2-benzazepine scaffold. Compound 14 (2-isobutyl-N-({[N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxamide) activates the CCR5 receptor in a CCL4-dependent manner, but does not compete with [3H]TAK-779 binding at the CCR5. Furthermore, introduction of a p-tolyl moiety at 7-position of the 2-benzazepine scaffold turns the CCR5 PAM 14 into the selective CCR2 receptor antagonist 26b. The structure affinity and activity relationships presented here offer new insights into ligand recognition by CCR2 and CCR5 receptors.

First total synthesis of isoquinolinone alkaloid marinamide and its methyl ester

The first total synthesis of isoquinolinone alkaloid marinamide 1 and its methyl ester 2 was described. The key steps involved a regioselective Friedel-Crafts reaction of 1-benzyl-1H-pyrrole to form the intermediate 8.

Total synthesis of a novel isoquinolinone alkaloid marinamide and its methyl ester

A naturally occurring isoquinolinone alkaloid marinamide and its methyl ester were synthesised from phthalic anhydride over eight steps in 46% and 52% overall yield. The key intermediate methyl 2-(1-benzyl-1H-pyrrole-2-carbonyl) benzoate was synthesised from the acid chloride of mono methyl phthalate and 1-benzyl-1H-pyrrole catalysed by Zinc oxide under solvent-free conditions at room temperature.

NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS

The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS

The present invention provides dihydroorotate dehydrogenase inhibitors of formula (I), methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, method